Martinsried, Germany, October 01, 2009 / b3c newswire / - KINAXO Biotechnologies GmbH announced today that it added KinAffinity to its service portfolio. KinAffinity provides invaluable information about a kinase inhibitors selectivity in a cell or tissue of interest. It simultaneously determines affinities for native kinases expressed within a cellular proteome and thus overcomes the limitations of traditional biochemical assays that only use recombinant proteins.
Kinase inhibitors with favorable pharmaceutical properties are extensively pursued as therapeutics in numerous oncological, neurological and inflammatory indications. However, their development faces significant challenges such as target specificity for the disease-relevant target proteins. Here, KinAffinity provides critical information to select the right lead compound for clinical development.
KinAffinity combines proprietary chemical proteomics methods with state-of-the-art quantitative mass spectrometry (see Sharma et al., Nature Methods 2009). Endogenously expressed, post-translationally modified kinases are enriched by a ready-to-use affinity matrix in the presence of native binding partners and competed with the kinase inhibitor of interest. Subsequently, bioinformatic methods are used to reveal the inhibitors quantitative cellular target profile. The inhibitors targets are ranked by their affinities and reported to the customer.
KinAffinity is applicable for type I and type II kinase inhibitors. It facilitates selectivity analysis on an organism level that accounts for differences in protein expression between different cells, as well as their mutational and modification status that might affect drug binding.
MEET KINAXO AT MIPTEC, BASEL, OCTOBER 13-15; AT CHI PIPELINE SUCCESS SUMMIT, BOSTON, OCTOBER 13-16 AND AT CHI DISCOVERY ON TARGET, BOSTON, NOVEMBER 2-4
About KINAXO www.kinaxo.com
KINAXO Biotechnologies GmbH is a privately-held biotechnology company based in Munich/Martinsried, Germany. As a spin-off of the Max Planck Institute of Biochemistry in Martinsried, we closely cooperate with several of the Institutes most outstanding scientists in the field of chemical proteomics and quantitative mass spectrometry, namely Dr. Henrik Daub, Prof. Jesper Olsen and Dr. Jrgen Cox. KINAXOs technology portfolio delivers direct insights into a compounds cellular interactions and its mode of action and is routinely applied to decrease drug development times and improve therapeutic strategies. To expand its KinAffinity platform, KINAXO recently received financial funding from the Bavarian Ministry of Economics. The underlying technology was licensed from the Max Planck Society and co-developed by scientists of the Max Planck Institute of Biochemistry and KINAXOs scientists.
KINAXO has several ongoing collaborations with major pharmaceutical and biotechnology companies such as Boehringer Ingelheim, Johnson & Johnson and Bayer, and is financed by European investors BioM, High-Tech Grnderfonds, KfW, the Max Planck Society, and Mountain Partners.
Dr. Jutta Fritz
Head of Technology and Business Development
KINAXO Biotechnologies GmbH
Am Klopferspitz 19a
82152 Martinsried, Germany
Phone +49 89 4613363-22